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OBJECTIVE: To assess the potential acute effects regarding the immunogenicity and safety of non-adjuvanted
influenza A H1N1/2009 vaccine in patients with mixed connective tissue disease and healthy controls.
METHODS: Sixty-nine mixed connective tissue disease patients that were confirmed by Kasukawa’s classification
criteria and 69 age- and gender-matched controls participated in the study; the participants were vaccinated
with the non-adjuvanted influenza A/California/7/2009 (H1N1) virus-like strain. The percentages of seroprotec-
tion, seroconversion, geometric mean titer and factor increase in the geometric mean titer were calculated. The
patients were clinically evaluated, and blood samples were collected pre- and 21 days post-vaccination to
evaluate C-reactive protein, muscle enzymes and autoantibodies. Anti-H1N1 titers were determined using an
influenza hemagglutination inhibition assay. ClinicalTrials.gov: NCT01151644.
RESULTS: Before vaccination, no difference was observed regarding the seroprotection rates (p=1.0) and
geometric mean titer (p=0.83) between the patients and controls. After vaccination, seroprotection (75.4% vs.
71%, p=0.7), seroconversion (68.1% vs. 65.2%, p=1.00) and factor increase in the geometric mean titer (10.0
vs. 8.0, p=0.40) were similar in the two groups. Further evaluation of seroconversion in patients with and
without current or previous history of muscle disease (p=0.20), skin ulcers (p=0.48), lupus-like cutaneous
disease (p=0.74), secondary Sjo¨gren syndrome (p=0.78), scleroderma-pattern in the nailfold capillaroscopy
(p=1.0), lymphopenia #1000/mm3 on two or more occasions (p=1.0), hypergammaglobulinemia $1.6 g/d
(p=0.60), pulmonary hypertension (p=1.0) and pulmonary fibrosis (p=0.80) revealed comparable rates.
Seroconversion rates were also similar in patients with and without immunosuppressants. Disease parameters,
such as C-reactive protein (p=0.94), aldolase (p=0.73), creatine phosphokinase (p=0.40) and ribonucleoprotein
antibody levels (p=0.98), remained largely unchanged pre and post-vaccination. No severe side effects were
reported.
CONCLUSIONS: The non-adjuvanted influenza A/H1N1 vaccination immune response in mixed connective tissue
disease patients is adequate and does not depend on the disease manifestations and therapy.
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& INTRODUCTION
In 2009, there was a worldwide influenza A H1N1/2009
virus pandemic that causedmany deaths and hospitalizations
and resulted in theWHO subsequently including this virus in
the trivalent seasonal flu vaccine (1,2).
Patients with systemic autoimmune diseases are particu-
larly susceptible to infections. This complication is an
important cause of mortality and morbidity, reinforcing
the importance of vaccination in this subgroup of patients.
Immunosuppressed patients have been overrepresented
among those who have experienced severe influenza A
H1N1/2009 virus infections, demanding specific recom-
mendations for the vaccination (3).
One dose of the non-adjuvant split-virion vaccine appears
to be effective and safe for people without rheumatic
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diseases (4). Regarding mixed connective tissue disease
(MCTD), there is only one study in the literature from our
group focusing solely on the side effects of the vaccine and
the overall immune response in a large cohort of patients
with systemic autoimmune diseases (5). However, there are
no data regarding the influence of disease and therapy on
the immunogenicity of influenza H1N1 vaccination in
MCTD. The possible effects of this vaccine on the clinical
and laboratory parameters of this disease are also unknown.
The aims of this study were therefore to evaluate the
possible influence of disease and therapy on the vaccination
immune response and the potential effect of the vaccine on
the clinical and laboratory MCTD parameters.
& METHODS
Study design and participants
This prospective study enrolled patients with MCTD
from the Outpatient Clinic of the Rheumatology Division,
Hospital das Clı´nicas da Faculdade de Medicina da
Universidade de Sa˜o Paulo, between March 22, 2010, and
April 2, 2010, during the public health influenza A H1N1/
2009 vaccine campaign for immunosuppressed patients.
The protocol was approved by the Local Institutional
Ethics Committee and registered in clinicaltrials.gov under
#NCT01151644.
All of the patients with an MCTD diagnosis regularly
followed at rheumatology outpatient clinics were invited by
letter to participate in the public health influenza A H1N1/
2009 vaccine campaign at the Immunization Center of the
same hospital. Healthy subjects who came to this center in
response to the public health national campaign were
invited to participate as control group.
After vaccination, there was a follow-up period of 21
days, during which the participants completed a personal
diary card of side effects. The patients were clinically
evaluated, and blood samples were collected pre- and 21
days post-vaccination. This period was chosen to evaluate
the humoral response to influenza vaccine and is in
accordance with previous studies (4).
We included the patients with MCTD who accepted the
invitation and attended two visits for clinical and safety
assessments and laboratory assays. All of the patients
fulfilled Kasukawa’s classification criteria (6). The healthy
subjects were matched by gender and age and were
included as the control group.
The participants were all $18 years of age and signed
informed consent forms. The exclusion criteria were as
follows: previous known infection with influenza A (H1N1)
in 2009; anaphylactic response to vaccine components or egg
proteins; acute infection with fever over 38 C˚ at the time of
vaccination; history of demyelinating syndromes or
Guillain-Barre´ syndrome; previous vaccination with any
live virus vaccine four weeks before inclusion or with any
inactivated virus vaccine two weeks before the recruitment;
seasonal flu vaccination in 2010; or blood transfusion within
6 months and hospitalization.
The doses of steroids and/or immunosuppressive agents
remained the same throughout the evaluation.
Vaccine
The H1N1 vaccine (batch #1002027) was produced by
Butantan Institute/Sanofi Pasteur (Sa˜o Paulo, Brazil) using a
novel monovalent, unadjuvanted, inactivated, split-virus
vaccine. The active substance was an inactivated split
influenza virus containing antigen equivalent to the A/
California/7/2009(H1N1) virus-like strain (NYMCx-179A),
one of the candidate reassortant vaccine viruses recom-
mended by the WHO. The vaccine was prepared in
embryonated chicken eggs using the same standard techni-
ques used to produce seasonal, trivalent, inactivated vaccine
and was presented in 5 ml multi-dose vials with thimerosal
added as a preservative (45 mg per 0.5 ml dose).
All of the participants received a single intramuscular
dose (0.5 ml) of 15 mg of hemagglutinin antigen specific
for pandemic H1N1 A/California/7/2009-like virus (A/
California/7/2009/Butantan Institute/Sanofi Pasteur) ad-
ministered by a member of the nursing staff from the
Immunization Center of Hospital das Clı´nicas, Medical
School, University of Sa˜o Paulo. The 69 patients with MCTD
and 69 healthy subjects were vaccinated from March 22 to
April 2, 2010.
Clinical assessments
The immune responses of the patients were analyzed
according to the clinical features that they presented after
their diagnosis with MCTD: muscle disease (muscle weak-
ness associated with at least a two-fold elevation of creatine
phosphokinase and/or aldolase in the absence of thyroid
disease, infections or myopathy-inducing drugs); skin
ulcers; SLE-like cutaneous disease (malar rash or photo-
sensitivity); secondary Sjo¨gren syndrome according to the
American European Consensus Group (AECG) criteria (7); a
scleroderma-pattern in nailfold capillaroscopy (presence of
avascular areas or enlarged loops associated with at least
one additional SD-parameter: microhemorrhages, reduced
capillary density, enlarged loops and avascular areas);
lymphopenia #1000 cells/mm3 on two or more occasions
(not induced by cytotoxic drugs); hypergammaglobulinemia
$1.6 mg/dl; pulmonary arterial hypertension (estimated
systolic pulmonary arterial pressure $40 mmHg or esti-
mated mean pulmonary arterial pressure .25 mmHg at
echocardiogram); or pulmonary disease (presence of
ground-glass opacity predominantly in the subcortical
region at lower pulmonary lobes on chest high resolution
computerized tomography).
Safety assessments
A 21-day diary card was given to each participant at the
beginning of the study. This card listed 13 established side
effects and requested yes or no responses. It also included
the following items: local reactions (pain, redness, swelling
and itching) and systemic adverse events (arthralgia, fever,
headache, myalgia, sore throat, cough, diarrhea, rhinorrhea
and nasal congestion). The diary cards were not pre-tested
and were based on the adverse events reported in previous
studies for the same vaccine in healthy subjects (4). The
patients were instructed to return the cards 21 days after the
vaccination for follow-up. All of the local reactions were
considered to be related to the vaccine. The recorded
systemic symptoms were checked by the investigators to
determine the causality of solicited adverse events.
Unsolicited adverse events were also assessed. Severe side
effects were defined as those that required hospitalization or
caused death.
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Laboratory assays
The immunogenicity of the H1N1 A/California/7/2009-
like virus vaccine was evaluated using a hemagglutination
inhibition assay (HIA) at the Adolfo Lutz Institute (Sa˜o
Paulo, Brazil). The influenza virus antigen used in this study
was the H1N1 A/California/7/2009 provided by the
Butantan Institute (Sa˜o Paulo, Brazil). The viral concentra-
tion was previously determined using hemagglutinin
antigen titration, and the HIA test was performed after
removing the naturally occurring non-specific inhibitors
from the sera as previously described. The immune
response to the H1N1 vaccination was evaluated by
determining the level of antibodies using HIA. The anti-
H1N1 titer was determined by influenza HIA. The
percentage of seroprotection (titer $1:40), seroconversion
(pre-vaccination titer ,1:10 and post-vaccination HIA titer
$1:40 or pre-vaccination titer $1:10 and post-vaccination
titer $4-fold increase), geometric mean titers (GMTs) and
factor increase in GMTs were calculated. The GMT is the
geometric mean of the titers, the simple arithmetic mean of
the logarithms of the last positive dilution of each serum.
The factor increase in GMTs is the ratio of the GMT after
vaccination to the GMT before vaccination.
The laboratory inflammatory activity of MCTD was
evaluated pre- and post-vaccination by measuring the levels
of aldolase, C-reactive protein (CRP) and creatine kinase
(CK) using standard methods. The anti-ribonucleoprotein
(anti-RNP) levels were also determined using an enzyme-
linked immunosorbent assay (ELISA) with a commercially
available kit (INOVA Diagnostics).
Statistical analysis
Two-sided 95% CIs were calculated assuming binomial
distributions for the dichotomous variables (Clopper-
Pearson method) and log normal distributions for the
hemagglutination inhibition titers. The categorical variables
were compared using Fisher’s exact test; the normally or
non-normally distributed variables were compared using a
t-test or Mann-Whitney rank sum test. All of the tests were
two-sided, with a 0.05 significance level.
& RESULTS
Seventy-five patients with MCTD accepted the invitation
to participate in the study, but only 69 returned for the
clinical and safety assessments and laboratory assays and
were included. Sixty-nine healthy controls were also
studied. As expected, the mean age (48.6¡12.6 vs. 48¡12,
p=0.7) and gender ratios (a female gender predominance;
95.6 vs. 95.6%, p= 1.00) of the patients and controls were
alike. The mean disease duration was 12.9¡8.9 years. The
frequencies of MCTD manifestations were as follows:
pulmonary fibrosis (52.2%), pulmonary arterial hyperten-
sion (20.3%), myositis (47.8%), lymphopenia (39.1%) and
hypergammaglobulinemia (59.4%). At the beginning of the
study, thirteen (18.84%) of the patients were not taking
any drugs. Thirty-one (44.9%) of the patients were taking
prednisone with a mean dose of 10.5¡7.2 mg/day. Current
use of immunosuppressive agents was observed in 45
(65.2%) of the patients as follows: azathioprine (42.2%),
methotrexate (28.9%), leflunomide (15.6%) and others
(13.3%) (Table 1).
Influenza A H1N1/2009 vaccine immunogenicity vs.
healthy controls
At study onset, the seroprotection rates (p= 1.0) and GMT
(p= 0.83) were similar between the patients and controls.
After vaccination, the seroprotection rate (75.4% vs. 71%,
p= 0.70), seroconversion rate (68.1% vs. 65.2%, p=1.0) and
factor increase in GMT (10.0 vs. 8.0, p= 0.40) remained
similar in both groups (Table 2).
Effect of therapy in the influenza A H1N1/2009
vaccine immune response
The comparison of MCTD patients post-vaccination with
and without therapy revealed comparable seroprotection
(p= 1.0), seroconversion (p= 1.0) and FI GMT (p=0.61).
Similarly, the seroconversion rates were alike in patients
with and without the following therapies: glucocorticoids
(p= 0.80), chloroquine (p= 0.79), azathioprine (p= 0.26),
methotrexate (p=1.0) and leflunomide (p= 0.68). Patients
with and without immunosuppressive agents also had a
similar post-vaccination seroprotection rate (75.6%; 95% CI,
62.3-88.9% vs. 75%; 95% CI, 59-91%; p= 1.0), FI GMT (13.5;
95% CI, 8.2-22.1 vs. 6.4; 95% CI, 4.3-9.5; p= 0.06) and
seroconversion rate (73.2%; 95% CI, 59.4-86.9 vs. 57.1; 95%
CI, 38.5-76%; p=0.2).
Effect of disease in the influenza A H1N1/2009
vaccine immune response
Analysis of clinical parameters revealed comparable rates
of seroconversion in MCTD patients with and without
current or previous history of the following factors: muscle
disease (75.7%; 95% CI, 60.9-90.6% vs. 58%; 95% CI, 42-
74.7%; p= 0.2), skin ulcers (80%; 95% CI, 53.9 - 106.1% vs.
64%; 95% CI, 52.1-76,7%; p= 0.48), SLE-like cutaneous
disease (72.7%; 95% CI, 45.1-100.3% vs. 66%; 95% CI, 53.2-
77.8%; p= 0.74), secondary Sjo¨gren syndrome (63.2%; 95% CI
40.9-85.4% vs. 67%; 95% CI, 54.1-80.6%; p= 0.78), nailfold
capillaroscopy scleroderma-pattern (65.8%; 95% CI, 50.5-
81.0 vs. 67%; 95% CI, 46-87.3%; p= 1.0), lymphopenia
#1000 cells/mm3 on two or more occasions (66.7%; 95%
Table 1 - Laboratory data before and after the
vaccination and treatment in 69 MCTD patients.
MCTD patients (n = 69)
Before vaccine After vaccine p-value
Laboratory data
ANTI-RNP (UI/ml) 2391.3 (1210.6) 2446.1 (1182.1) 0.98
CRP (mg/dl) 9.3 (13.4) 9.6 (13.9) 0.94
Aldolase 4.2 (2.8) 4.5 (3.0) 0.73
CK 199.3 (231.8) 153.1(152.7) 0.40
Treatment
Corticosteroids, n (%) 31 (44.9)
mean dose, mg/day 10.5 (7.2)
Chloroquine, n (%) 25 (36.2)
Azathioprine, n (%) 19 (27.5)
mean dose, mg/day 137.5 (42.2)
Methotrexate, n (%) 13 (18.8)
mean dose, mg/day 18.2 (5.9)
Leflunomide, 20 mg/day, n
(%)
7 (10.1)
Data are expressed as numbers (%) or means (SD) unless otherwise
specified. The medications that were prescribed to less than 10% of the
patients were not included. CRP, C-reactive protein; CK, creatine kinase.
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CI 48.6-84.8% vs. 68%; 95% CI, 52.8-82.2%; p= 1.0), hyper-
gammaglobulinemia $1.6 g/d (63.4%; 95% CI, 48.5-78.3 vs.
71%; 95% CI, 52.3-89.4%; p=0.60), pulmonary arterial
hypertension (64.3; 95% CI, 38.2 - 90.3% vs. 67%; 95% CI
54.8 - 79.8%; p= 1.0) and pulmonary fibrosis (63.9%; 95% CI,
47.9 - 79.8 vs. 69.7%; 95% CI, 53.8 - 85.6%; p= 0.80).
Vaccine safety
No severe side effects were reported. The frequencies of
minor local reactions were similar between the patients and
controls (13% vs. 29%, p= 0.11). The systemic reaction that
was most frequently reported by patients was myalgia
(11.5%), but the reported level was not different relative to
that of the controls (p= 1.0).
& DISCUSSION
This is the first study to determine that the immune
response to influenza H1N1 vaccine in MCTD patients is
adequate and independent of the clinical aspects of the
disease and therapy.
Regarding other rheumatic diseases, we and others have
previously demonstrated appropriate pandemic 2009 influ-
enza A (H1N1) response and vaccine safety in patients
with rheumatoid arthritis, ankylosing spondylitis, systemic
sclerosis, psoriatic arthritis, Behc¸et’s disease, primary anti-
phospholipid syndrome, dermatomyositis, primary Sjo¨gren
syndrome, Takayasu’s arteritis, polymyositis, granuloma-
tous polyangiitis and juvenile autoimmune rheumatic
disease (juvenile systemic lupus erythematosus (SLE),
juvenile idiopathic arthritis, juvenile dermatomyositis,
juvenile scleroderma, and vasculitis) compared with healthy
controls (5,8,9). In contrast, similar studies with SLE patients
have demonstrated an impairment in the immune response
to influenza vaccination evaluated by the assessment of
autoantibodies (10-12). It is possible that these discrepancies
could be related to variations in the diseases, variations in
the vaccines and the usage of several medications.
No harmful effect of the disease was observed, which may
be related to the use of unadjuvanted vaccine in the present
study. Unadjuvanted vaccines offer the theoretical advantage
of minimizing the risk of potentiating the humoral response
and avoiding the autoimmune/inflammatory syndrome
induced by adjuvants (ASIA) (13). However, a large meta-
analysis revealed no difference in the incidence of adverse
events of autoimmune origin between subjects who received
influenza vaccinations with and without adjuvant (14).
In contrast with SLE, in which several activity indexes are
available and widely used (15) and there are well-defined
serological markers, such as anti-dsDNA and complement
levels (16), there are no such tools for MCTD. In SLE,
controversy remains regarding whether disease flare occurs
after immunization with H1N1 vaccination (10,17) and
whether there are changes in the levels of SLE-related auto
antibodies (10,18). In this group of MCTD patients, the
stability of the clinical, laboratory and treatment parameters
throughout the study supports the notion that pandemic
H1N1 is not harmful to this disease.
Conversely, the possible influence of disease manifesta-
tion in the post-vaccination immune response is a matter of
concern, but none of the clinical or laboratory MCTD
parameters evaluated were associated with a diminished
humoral response. In contrast, the efficacy of the H1N1
pandemic vaccine was impaired in lupus patients with
lymphopenia (19), and in HIV-infected individuals, a lower
mean nadir CD4 cell count and longer duration of infection
were associated with reduced seroconversion (20).
Despite the use of immunosuppressive drugs, MCTD
patients did not present any impairment in their immune
response. The influenza vaccine response appears to differ in
individual rheumatic diseases (5). In this regard, our large
cohort analysis of 555 lupus patients revealed that immuno-
modulators appear to be a more relevant factor for a reduced
pandemic vaccine immune response than the disease itself
(21). Similarly, we observed a methotrexate-impaired H1N1
vaccine-induced humoral response in RA patients (22). In
children with systemic autoimmune diseases, glucocorticoid
was identified as the only drug that decreased seroconversion
in multivariate analysis (9). Immunosuppressive drugs, such
as methotrexate, azathioprine, leflunomide, mycophenolate
Table 2 - Seroprotection, seroconversion, geometric mean titers and factor increase in geometric mean titers before and
after vaccination.
Pre-vaccination Post-vaccination
Subset GMT Seroprotection GMT Seroprotection FI in GMT Seroconversion
MCTD 8.3 (6.8-10.3) 10.1 (3.0-17.2) 83.3 (59.0-117.6) 75.4 (65.2-85.6) 10.0 (7.0-14.2) 68.1 (57.1-79.1)
Controls 8.3 (6.9-9.9) 10.1 (2.9-17.3) 66.1 (49.6-88.1) 71 (60.2-81.8) 8.0 (6.0-10.6) 65.2 (53.9-76.5)
Glucocorticoid
Yes 8.9 (6.2-12.8) 13.0 (1.0-25.0) 78.2 (42.9-142.4) 74.0 (59.0-90.0) 8.7 (4.8-15.9) 65.0 (47.0-82.0)
No 7.9 (6.2-9.8) 7.9 (-0.7-16.6) 87.6 (59.9-128.2) 76.3 (62.6-90.0) 11.1 (7.5-16.4) 68.4 (53.4-83.4)
Chloroquine
Yes 7.8 (5.7-10.6) 8.0 (-3.0-19.0) 67.7 (41.4-110.7) 76.0 (59.0-93.0) 8.7 (5.0-14.8) 64.0 (45.0-83.0)
No 8.6 (6.6-11.3) 11.3 (1.8-20.8) 93.6 (59.5-147.2) 75.0 (62.0-87.9) 10.8 (6.9-16.8) 68.1 (54.2-82.1)
Azathioprine
Yes 7.7 (5.4-10.9) 1.1 (-0.05-1.16) 119.5 (55.9-255.1) 79 (60.0-98.0) 15.4 (2.0-31.3) 79.0 (60.0-98.0)
No 8.6 (6.7-11.0) 1.1 (1.0-1.23) 72.6 (50.3-104.7) 74 (61.7-86.3) 8.4 (5.7-12.4) 62.0 (48.4-75.6)
Methotrexate
Yes 6.5 (4.2-9.9) 8.0 (-7.0-23.0) 49.5 (27.0-90.5) 77 (53-101.0) 7.6 (3.8-14.9) 69.0 (43.0-95.0)
No 8.8 (7.0-11.1) 10.7 (2.5-18.8) 93.9 (63.7-138.6) 75 (63.5-86.4) 10.6 (7.1-15.7) 66.0 (53.5-78.6)
Leflunomide
Yes 8.2 (3.8-17.7) 14.3 (-13.7-42.3) 119.5 (55.9-255.1) 79.0 (60.0-98.0) 15.4 (2.0-31.3) 79.0 (60.0-98.0)
No 8.3 (6.7-10.3) 9.6 (2.2-17.0) 73.9 (53.4-102.5) 75.8 (65.0-86.5) 8.8 (6.4-12.1) 67.7 (56.0-79.4)
Data are expressed in percentages or values (95% CI). GMT, geometric mean titer; FI in GMT, factor increase in GMT after vaccination; MCTD, mixed
connective tissue disease.
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mofetil, cyclosporine and glucocorticoid, were associated
with lower antibody titers in patients with inflammatory
rheumatic diseases (9,11,23).
The non-adjuvanted influenza A/H1N1 vaccination
immune response in MCTD patients is appropriate and
independent of their disease manifestations and therapies.
In addition, the overall vaccine safety supports its recom-
mendation.
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